Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiyoutai vs Ozempic in Type 2 Diabetes
NCT05816057Phase 3Completed
- Sponsor
- Jiuyuan Gene Engineering
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Jiyoutai in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jiuyuan Gene Engineering. Primary endpoint: Glycosylated Haemoglobin A1c at 32 weeks. Started Jul 2022; status: completed.
02
Drugs
Jiyoutai
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05816057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816057.